Why the study?
Reduced cardiovascular reserve and exercise intolerance are common in CKD and linked to adverse outcomes, warranting a review of CPET methodology and applications in pre-dialysis CKD.
CPET is a comprehensive tool for evaluating exercise intolerance and cardiovascular risk in patients with pre-dialysis CKD, with potential applications in risk stratification and as an intermediate endpoint in clinical trials.
Answers are grounded in this paper and cite their sources.
Supports CPET for exercise limitation assessment in CKD; leaves open routine adoption pending prospective validation.
BACKGROUND: Chronic kidney disease (CKD) is often characterized by increased prevalence of cardiovascular risk factors and increased incidence of cardiovascular events and death. Reduced cardiovascular reserve and exercise intolerance are common in patients with CKD and are associated with adverse outcomes. SUMMARY: The gold standard for identifying exercise limitation is cardiopulmonary exercise testing (CPET). CPET provides an integrative evaluation of cardiovascular, pulmonary, hematopoietic, neuropsychological, and metabolic function during maximal or submaximal exercise. It is useful in clinical setting for differentiation of the causes of exercise intolerance, risk stratification, and assessment of response to relevant treatments. A number of recent studies have used CPET in patients with pre-dialysis CKD, aiming to assess the cardiovascular reserve of these individuals, as well as the effect of interventions such as exercise training programs on their functional capacity. This review provides an in-depth description of CPET methodology and an overview of studies that utilized CPET technology to assess cardiovascular reserve in patients with pre-dialysis CKD. Key Messages: CPET can delineate multisystem changes and offer comprehensive phenotyping of factors determining overall cardiovascular risk. Potential clinical applications of CPET in CKD patients range from objective diagnosis of exercise intolerance to preoperative and long-term risk stratification and providing intermediate endpoints for clinical trials. Future studies should delineate the association of CPET indexes, with cardiovascular and respiratory alterations and hard outcomes in CKD patients, to enhance its diagnostic and prognostic utility in this population.
No takes yet. Share an insight, caveat, or question.
Pella et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: